A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies (MDX1106-01)

Clinical Trial ID NCT00441337

PubWeight™ 28.85^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00441337

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.	J Clin Oncol	2010	17.13
2	Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.	Trends Mol Med	2014	1.59
3	B7 family checkpoint regulators in immune regulation and disease.	Trends Immunol	2013	1.53
4	Novel targeted therapeutics for metastatic castration-resistant prostate cancer.	Cancer Lett	2009	1.04
5	Tumor evasion from T cell surveillance.	J Biomed Biotechnol	2011	1.01
6	Role of immunotherapy for renal cell cancer in 2011.	J Natl Compr Canc Netw	2011	0.91
7	Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.	Int J Mol Sci	2013	0.88
8	Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.	Cancer J	2014	0.88
9	Targeting the PD-1 pathway: a promising future for the treatment of melanoma.	Arch Dermatol Res	2014	0.87
10	PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence.	Onco Targets Ther	2014	0.85
11	Evolving Concepts: Immunity in Oncology from Targets to Treatments.	J Oncol	2015	0.81
12	PD-1 and PD-L1 antibodies for melanoma.	Hum Vaccin Immunother	2014	0.80
13	Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy.	J Clin Immunol	2011	0.78
14	Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.	J Transl Med	2016	0.77
15	Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma.	ESMO Open	2016	0.77